Relationships Between SLC26A7 Expressions and Extra-Thyroid Metastasis of Papillary Thyroid Carcinoma
Papillary thyroid carcinoma (PTC) represents over 80% of thyroid cancer cases. While generally associated with favorable outcomes, a subset of PTCs exhibits aggressive behavior, including extra-thyroid metastasis, which significantly reduces the 5-year survival rate. The molecular mechanisms driving metastasis in PTC remain poorly understood. Recent studies have implicated solute carrier family 26 member 7 (SLC26A7), an anion transporter involved in iodide transport and thyroid hormonogenesis, in thyroid carcinogenesis. This study investigates the relationship between SLC26A7 expression, clinicopathological features, and extra-thyroid metastasis in PTC, while exploring potential triggers for SLC26A7 dysregulation.
Data Acquisition and Differential Gene Expression Analysis
Three microarray datasets—GSE129562, GSE60542, and GSE6004—were obtained from the Gene Expression Omnibus (GEO) repository. These datasets included metastatic PTC tumors and adjacent normal thyroid tissues. Using GEO2R, differentially expressed genes (DEGs) were identified with thresholds of adjusted P 1. A total of 190 overlapping DEGs were identified across all three datasets: 102 up-regulated and 88 down-regulated. These included genes such as SLC26A7, which was selected for further analysis due to its emerging role in thyroid function and carcinogenesis.
Functional Annotation of Differentially Expressed Genes
Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses were performed using DAVID v6.8. Up-regulated DEGs were enriched in pathways related to cancer progression, wound healing, extracellular exosomes, and protein homodimerization. Down-regulated DEGs were linked to mineral absorption, zinc ion response, extracellular space, and calcium ion binding. These findings suggest that metastatic PTC involves a complex interplay of pathways affecting cell adhesion, ion transport, and extracellular matrix remodeling.
SLC26A7 Expression and Clinical Correlations
Survival and Staging Analysis
Analysis of The Cancer Genome Atlas (TCGA) data revealed that low SLC26A7 expression correlated with shorter disease-free survival (DFS) and progression-free survival (PFS). Tumors with reduced SLC26A7 expression were associated with advanced disease stages, highlighting its potential as a prognostic marker.
Experimental Validation in Patient Cohorts
A hospital-based cross-sectional study validated these findings using 35 PTC specimens and adjacent normal tissues. Real-time polymerase chain reaction (RT-PCR) showed that 34.3% (12/35) of tumors exhibited down-regulated SLC26A7 compared to normal tissue. Patients with low SLC26A7 expression had a significantly higher rate of extra-thyroid metastasis (83.3% vs. 43.5%, P = 0.026). Logistic regression confirmed low SLC26A7 as an independent risk factor for metastasis (odds ratio [OR] = 7.108; 95% confidence interval [CI]: 1.048–48.218; P = 0.045).
Impact of Iodine Nutrition Status
Urinary iodine concentration (UIC), a marker of iodine intake, was assessed to explore triggers for SLC26A7 dysregulation. High UIC (> 300 μg/L) correlated with reduced SLC26A7 expression (50.0% vs. 17.6% in non-high UIC groups; P = 0.047) and increased metastasis (77.8% vs. 35.3%; P = 0.013). Multivariate analysis identified high UIC as an independent predictor of both low SLC26A7 (OR = 5.980; 95% CI: 1.067–33.515; P = 0.042) and metastasis (OR = 6.846; 95% CI: 1.352–34.664; P = 0.020). Animal studies cited in the paper suggest that excessive iodine suppresses iodide transporters, potentially promoting genomic hypomethylation and carcinogenesis.
Mechanistic Insights and Biological Significance
SLC26A7, recently identified as a thyroid iodide transporter, is critical for hormonogenesis. Dysregulation may impair iodide uptake, leading to hypothyroidism and goiter. In cancer, suppressed SLC26A7 could promote metastasis by altering methylation patterns, though the exact pathways require further exploration. The study posits that high iodine intake disrupts SLC26A7 expression, creating a permissive environment for tumor invasion.
Limitations and Future Directions
The cross-sectional design and small sample size (n = 35) limit causal inferences. While public database analyses (GEO, TCGA) strengthen validity, experimental models are needed to confirm mechanisms. Future studies should investigate SLC26A7’s role in methylation regulation and validate iodine’s effects in animal models.
Conclusion
This study establishes SLC26A7 down-regulation as a key factor in PTC metastasis, potentially triggered by high iodine exposure. The findings underscore the need for monitoring iodine intake in PTC patients and highlight SLC26A7 as a therapeutic target. Further research is required to elucidate the molecular pathways linking iodine, SLC26A7, and metastasis.
doi.org/10.1097/CM9.0000000000001662
Was this helpful?
0 / 0